

JAMA Dermatology | Consensus Statement

The Alopecia Areata Severity and Morbidity Index (ASAMI) Study Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity

ASAMI Consensus Survey Study Group

IMPORTANCE Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact.

OBJECTIVE To explore factors associated with AA severity beyond scalp hair loss, and to support the development of the Alopecia Areata Severity and Morbidity Index (ASAMI).

EVIDENCE REVIEW A total of 74 hair and scalp disorder specialists from multiple continents were invited to participate in an eDelphi project consisting of 3 survey rounds. The first 2 sessions took place via a text-based web application following the Delphi study design. The final round took place virtually among participants via video conferencing software on April 30, 2022.

FINDINGS Of all invited experts, 64 completed the first survey round (global representation: Africa [4.7%], Asia [9.4%], Australia [14.1%], Europe [43.8%], North America [23.4%], and South America [4.7%]; health care setting: public [20.3%], private [28.1%], and both [51.6%]). A total of 58 specialists completed the second round, and 42 participated in the final video conference meeting. Overall, consensus was achieved in 96 of 107 questions. Several factors, independent of the Severity of Alopecia Tool score, were identified as potentially worsening AA severity outcomes. These factors included a disease duration of 12 months or more, 3 or more relapses, inadequate response to topical or systemic treatments, rapid disease progression, difficulty in cosmetically concealing hair loss, facial hair involvement (eyebrows, eyelashes, and/or beard), nail involvement, impaired quality of life, and a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA. Consensus was reached that the Alopecia Areata Investigator Global Assessment scale adequately classified the severity of scalp hair loss.

CONCLUSIONS AND RELEVANCE This eDelphi survey study, with consensus among global experts, identified various determinants of AA severity, encompassing not only scalp hair loss but also other outcomes. These findings are expected to facilitate the development of a multicomponent severity tool that endeavors to competently measure various disease impact. The findings are also anticipated to aid in identifying candidates for current and emerging systemic treatments. Future research must incorporate the perspectives of patients and the public to assign weight to the domains recognized in this project as associated with AA severity.

 Supplemental content

 CME at jamacmelookup.com

Alopecia areata (AA) is a clinically heterogeneous disease characterized by variable degrees of nonscarring hair loss.¹ The estimated lifetime risk of developing AA is between 1.7% and 2.1%²⁻⁴ with 7.8 to 12.5 million people affected globally at any given time.^{5,6} The chronic and relapsing nature of AA can lead to clinically significant psychosocial morbidity that can accumulate, contributing to increased distress, sleep disorders, anxiety, depression, and suicidality.^{7,8} Furthermore, when compared with the general population, patients with AA are more likely to require time off work or have antidepressants prescribed.⁹

Widely used measures of AA severity, such as the Severity of Alopecia Tool (SALT), have predominantly focused on the extent of scalp hair loss, without consideration of non-scalp hair loss or the psychosocial domains of disease.¹⁰⁻¹² Recently, multidimensional assessment tools such as the Alopecia Areata Severity Scale have been proposed in an attempt to capture the multiple patient- and illness-related domains of AA.¹³

Insights into the etiopathogenesis of AA have led to the emergence of several novel, highly effective treatments, including Janus kinase (JAK) inhibitors.^{14,15} Baricitinib, a selective and reversible JAK1/JAK2 inhibitor is now approved by the US Food and Drug Administration,¹⁶ European Medicines Agency,¹⁷ and Medicines & Healthcare Products Regulatory Agency¹⁸ for the treatment of severe AA in adults. A global consensus of AA experts agreed that “if all treatments were equally reimbursed, JAK inhibitors would be the ideal choice of systemic therapy in adults”¹⁹; however, the substantial cost of JAK inhibitor medication could be prohibitive.²⁰ In resource-limited settings, severity assessment tools that adequately capture the multidimensional burden of AA will help to equitably identify the most appropriate candidates for current and emerging therapies. Through expert consensus, this project aimed to complement existing international efforts^{12,13} by identifying key factors that determine AA disease burden, establishing severity thresholds for the initiation of systemic treatment, and recognizing relevant considerations pertaining to the funding of JAK inhibitors for treatment. This study’s findings will play a crucial role in shaping the development of the Alopecia Areata Severity and Morbidity Index (ASAMI), a proposed multidimensional AA severity assessment tool.

Methods

This study was reported with reference to a checklist developed for similar Delphi exercises²¹⁻²³ and followed the Standards for Quality Improvement Reporting Excellence (SQUIRE) 2.0 reporting guideline.²⁴⁻²⁶ Consistent with previous studies of a similar nature, the Medical Research Involving Human Subjects Act was not applicable to this study.^{5,19,26}

Expert Panel Selection

A total of 74 hair and scalp disorder specialists from 6 continents were invited to participate in a 3-round eDelphi process. In the pursuit of fostering a diverse array of international perspectives, invitations were extended based on previous involvement in international AA research projects, recommendations from individuals with a history of presenting at international conferences or publishing in peer-reviewed journals, or endorsements from international hair research societies.

Key Points

Question What are the key factors that determine alopecia areata severity?

Findings This preliminary global consensus survey study, consisting of 64 hair and scalp disorder specialists from 6 continents, identified several key factors associated with alopecia areata severity independent of the extent of scalp hair loss.

Meaning The findings from this study pave the way for the development of a comprehensive and multicomponent severity tool that aims to effectively measure disease impact and identify candidates for current and emerging systemic treatments.

eDelphi Process

The Delphi process is a validated technique utilized to achieve convergence of viewpoints from experts on predetermined topic areas.^{24,27,28} Participants iteratively answer a questionnaire through successive rounds; each round enables participants to review their answers while considering the anonymous replies of other participants.^{24,27,28} Unlike the traditional Delphi process, which consists of 2 or more rounds of face-to-face interactions, the eDelphi process empowers expert participants to anonymously engage online and asynchronously in their own time.^{4,19,26,29}

ASAMI eDelphi Survey

The primary questionnaire was designed by a panel of 7 clinicians with extensive AA experience. A comprehensive literature search was performed to ascertain critical determinants of AA severity. Four main categories were identified: disease surface area, disease activity, disease visibility, and psychosocial morbidity (Table 1). We formulated questions within these domains to identify objective factors that increased AA disease severity, determine thresholds for initiation of systemic treatment based on severity, and discern important considerations regarding the funding of JAK inhibitors for treating AA. The ASAMI questionnaire’s design acknowledged variation in AA treatment and that the use of systemic treatment may not be widespread. The questionnaire was distributed electronically using the Welphi online platform³⁰ for round 1 and round 2. The third round was conducted through a video conferencing meeting (Zoom Video Communications),³¹ with the Delphi questionnaire distributed via Poll Everywhere software (Poll Everywhere).³²

The questionnaire included a total of 107 statements and questions, with 79 using a 5-point Likert scale^{33,34} and 28 in a non-Likert-type format. Participants rated their agreement with Likert-type statements on a 5-point scale, ranging from strongly agree (1) to strongly disagree (5). Non-Likert questions encompassed free-text and multiple-choice formats, and participants had the option to mark not applicable where appropriate. When responding to the questionnaire, participants subjectively defined a low SALT score (LSS) as being just below the threshold at which they would consider a patient consistently eligible for systemic treatment. The questionnaire included instructions to contextualize statements. The consensus threshold for Likert-type and multiple-choice statements was defined as at least 66% participant agreement or disagreement. Free-text questions were not subjected to consensus thresholds but were used to explore participant attitudes. Likert-type and multiple-choice statements that did not achieve consensus were included in

Table 1. ASAMI Key Consensus Outcomes on Factors Affecting Alopecia Areata Disease Severity^a

Questionnaire domain	Consensus agreement, %
Disease surface area	
I agree with the AA-IGA scale's interpretation of scalp disease severity.	79.7
Disease activity	
Disease duration	
In a patient with a low SALT score, the duration of an AA episode may increase disease severity.	79.7
Severity of AA is increased by an episode duration lasting ≥12 months.	81.0
Relapse history	
In a patient with a low SALT score, a history of disease relapse may increase AA severity.	73.4
≥3 Lifetime relapses increase AA disease severity.	88.9
Refractory disease	
A history of inadequate response to topical and/or intralesional agents may increase AA severity.	85.9
As a minimum, 2 topical and/or intralesional agents must be trialed before defining an inadequate response.	95.0
A history of inadequate response to systemic therapy may increase AA severity.	93.8
As a minimum, 2 systemic agents must be trialed before defining an inadequate response.	89.5
Trichoscopy and other examination findings	
Trichoscopy provides meaningful information in the assessment of AA disease severity.	73.4
Trichoscopic features associated with adverse prognosis (such as yellow dots and broken hairs), increase AA severity.	85.0
In a patient with a low SALT score:	
A diffuse positive hair pull test increases AA disease severity rating.	92.2
Rapid progression of hair loss over weeks increases AA disease severity rating.	89.1
An ophiasis distribution increases overall AA severity rating.	85.9
Disease visibility	
Ability to cosmetically camouflage/conceal AA	
The presence of AA patches in more visible areas of the scalp increases disease severity rating irrespective of SALT score.	87.9
In a patient with a low SALT score, an inability (or difficulty) to cosmetically conceal/camouflage AA increases disease severity rating.	70.3
Eyebrow involvement (including extent and severity)	
Limited eyebrow disease in AA is defined by the presence of minimal gaps in eyebrow hair with even distribution (corresponding to Eyebrow ClinRO Measure 1).	92.2
Moderate eyebrow disease in AA is defined by the presence of significant gaps in eyebrow hair or uneven distribution (corresponding to Eyebrow ClinRO Measure 2).	93.8
Severe eyebrow disease in AA is defined by the presence of no eyebrow hair (corresponding to Eyebrow ClinRO Measure 3).	95.3
Eyebrow hair involvement should be incorporated into the overall assessment of AA severity as opposed to being assessed separately.	82.8

(continued)

Table 1. ASAMI Key Consensus Outcomes on Factors Affecting Alopecia Areata Disease Severity^a (continued)

Questionnaire domain	Consensus agreement, %
In a patient with a low SALT score:	
Concurrent unilateral eyebrow hair involvement increases scalp AA severity.	75.0
Concurrent bilateral eyebrow hair involvement increases scalp AA severity.	81.3
Eyebrow hair involvement that results in functional or occupational impairment increases scalp AA severity.	82.8
Eyelash involvement (including extent and severity)	
Limited eyelash disease in AA is defined by the presence of minimal gaps in eyelash hair with even spacing along the eyelids on both eyes (corresponding to Eyelash ClinRO Measure 1).	93.8
Moderate eyelash disease in AA is defined by the presence of significant gaps in eyelash hair or uneven spacing along the eyelids (corresponding to Eyelash ClinRO Measure 2).	95.3
Severe eyelash disease in AA is defined by the presence of no notable eyelashes (corresponding to Eyelash ClinRO Measure 3).	96.9
Eyelash hair involvement should be incorporated into the overall assessment of AA severity as opposed to being assessed separately.	78.1
In a patient with a low SALT score:	
Concurrent unilateral eyelash hair involvement increases scalp AA severity.	78.1
Concurrent bilateral eyelash hair involvement increases scalp AA severity.	79.7
Eyelash hair involvement that results in functional or occupational impairment increases scalp AA severity.	85.9
Beard involvement	
Beard hair involvement should be incorporated into the overall assessment of AA severity as opposed to being assessed separately.	75.9
In a patient with a low SALT score, concurrent beard hair involvement increases scalp AA severity. (Assume that the beard has no cultural or religious significance when answering this question.)	70.7
Nail involvement	
Mild nail disease in AA is defined by at least 1 nail being a little damaged (eg, pitted, rough, brittle, split) (corresponding to Nail ClinRO Measure 1).	84.4
Moderate nail disease in AA is defined by at least 1 nail being a moderately damaged (eg, pitted, rough, brittle, split) (corresponding to Nail ClinRO Measure 2).	84.4
Severe nail disease in AA is defined by at least 1 nail being very damaged (eg, pitted, rough, brittle, split) or the loss of at least 1 nail (corresponding to Nail ClinRO Measure 3).	81.3
Nail involvement should be incorporated into the overall assessment of AA severity as opposed to being assessed separately.	75.9
In a patient with a low SALT score:	
Nail involvement increases scalp AA severity.	70.3
Nail involvement that results in functional or occupational impairment is sufficient criteria for commencing systemic therapy.	76.6
Quality of life and psychosocial morbidity	
The psychosocial impact of disease is an important criterion when assessing AA severity.	87.5

(continued)

Table 1. ASAMI Key Consensus Outcomes on Factors Affecting Alopecia Areata Disease Severity^a (continued)

Questionnaire domain	Consensus agreement, %
In a patient with a low SALT score, the following increases the overall severity of AA:	
A history of anxiety due to or exacerbated by AA.	81.3
A history of depression due to or exacerbated by AA.	84.4
A history of suicidal ideation due to or exacerbated by AA.	82.8
In a patient with a low SALT score:	
Racial, ethnic, or religious factors may increase the overall severity of AA. (For example, consider a patient with beard AA, where the beard has a special cultural or religious significance.)	70.3
Impaired quality of life (as measured by DLQI) increases AA severity.	81.3
A DLQI score of <6 does not affect the overall severity rating of AA.	Range, 71.9-82.8
A DLQI score of ≥6 upgrades the overall severity rating of AA.	Range, 74.1-81.3

Abbreviations: AA, alopecia areata; AA-IGA, Alopecia Areata Investigator Global Assessment; ASAMI, Alopecia Areata Severity and Morbidity Index; DLQI, Dermatology Life Quality Index; SALT, Severity of Alopecia Tool.

^a A detailed record of survey questions and participant responses across the 3 rounds can be found in eFiles 1 and 2 in Supplement 1.

the subsequent eDelphi round. Statements achieving consensus were excluded from the next round. A detailed record of survey questions and participant responses across the 3 rounds can be found in eFiles 1 and 2 in Supplement 1.

Statistical Analysis

The data analysis was performed using SPSS Statistics, version 28.0 (IBM).³⁵ Categorical data were presented in terms of frequency and percentages. The results from non-Likert-type questions were presented in a qualitative manner.

Results


Expert Panel

Figure 1 summarizes expert participation in the ASAMI eDelphi project. Of the 74 invited expert participants, 64 (86.5%) completed round 1, 58 (78.4%) completed round 2, and 42 (56.8%) completed round 3. Representation from 6 continents was achieved, with the following distribution: Africa (3; 4.7%), Asia (6; 9.4%), Australia (9; 14.1%), Europe (28; 43.8%), North America (15; 23.4%), and South America (3; 4.7%). A total of 60 experts (93.8%) reported routinely treating adults and children with hair loss disorders. Thirteen participants (20.3%) exclusively worked in public practice, 18 (28.1%) exclusively in private practice, and 33 (51.6%) in both.

ASAMI Rounds

Figure 2 summarizes the ASAMI eDelphi rounds, encompassing 107 questions regarding disease surface area, disease duration, number of AA episodes, relapse history, refractory disease, trichoscopy findings, examination findings, the ability to conceal disease, psychosocial morbidity, and factors pertaining to third-party funding of JAK in-

Figure 1. Expert Participation in the Alopecia Areata Severity and Morbidity Index (ASAMI) eDelphi Project



This flowchart provides an overview of the number and characteristics of the experts involved in the ASAMI eDelphi project.

hibitors. Round 1 achieved consensus in 54 of 104 questions, round 2 achieved consensus in 21 of 46 questions, and the final session conducted via video communication software achieved consensus in 21 of 27 questions. During this final session, 1 question was split into 2 parts, and an additional question regarding the use of the Dermatology Life Quality Index (DLQI) was included based on expert dialogue. Overall, consensus was achieved in 96 of 107 questions.

Consensus Outcomes
Assessment of Disease Severity

Disease Surface Area (Scalp Involvement) | Consensus agreement was reached for the accurate classification of scalp AA severity using the Alopecia Areata Investigator Global Assessment scale.³⁶ In this classification, limited disease is defined by a SALT score between 1 and 20, moderate as SALT score between 21 and 49, severe as SALT score between 50 and 94, and very severe as SALT score between 95 and 100.


Disease Duration | Consensus was achieved that AA severity is increased by an episode lasting more than 12 months. Additionally, participants agreed that in a patient with LSS, the duration of an AA episode may increase disease severity.

Number of AA Episodes and Relapse History | Consensus was achieved that AA severity is increased by a history of 3 or more relapses. Additionally, participants agreed that in a patient with LSS, a previous history of disease relapse may increase disease severity.

Refractory Disease | There was agreement that a history of inadequate response to topical treatments (eg, corticosteroids, immunotherapy, dithranol, and minoxidil) and/or intralesional agents may increase AA severity. As a minimum, 2 topical and/or intralesional agents must be trialed before defining an inadequate response.

Participants also agreed that a history of inadequate response to systemic therapy (eg, systemic corticosteroids [including oral, intramuscular, or intravenous administration] azathioprine, cyclospor-

Figure 2. Summary of Alopecia Areata Severity and Morbidity Index (ASAMI) eDelphi Project Rounds



ine, methotrexate, and JAK inhibitors) may increase AA severity. As a minimum, 2 systemic agents must be trialed before defining an inadequate response.

Trichoscopy and Examination Findings | It was agreed that trichoscopy provides meaningful information in the assessment of AA disease severity and that trichoscopic features associated with adverse prognosis increase AA severity. In patients with LSS, the factors that increase AA disease severity rating include a diffuse positive hair pull test result, rapid progression of hair loss over weeks, and/or an ophiasis distribution.

Cosmetic Camouflage | The experts concurred that, in a patient with LSS, the disease severity rating is increased by challenges in cosmetically concealing or camouflaging their condition. Additionally, the presence of AA patches in more visible areas of the scalp, regardless of the overall SALT score, was associated with increased severity ratings.

Nonscalp Involvement |

Eyebrow Involvement The consensus among the experts was that eyebrow hair involvement should be incorporated into the overall assessment of AA severity, rather than assessing eyebrows separately. Additionally, the participants agreed that, in a patient with LSS, concurrent unilateral or bilateral eyebrow involvement was associated with heightened overall AA severity. The experts also concurred that in a patient with LSS, eyebrow hair involvement resulting in functional or occupational impairment was associated with increased severity of scalp AA.

- The experts agreed regarding the severity of eyebrow disease:
- Minimal gaps with even distribution indicated limited eyebrow disease (corresponding to Eyebrow ClinRO Measure 1³⁷).

- Significant gaps or uneven distribution indicated moderate eyebrow disease (corresponding to Eyebrow ClinRO Measure 2³⁷).
- No eyebrow hair indicated severe eyebrow disease (corresponding to Eyebrow ClinRO Measure 3³⁷).

Eyelash Involvement Participants agreed that eyelash hair involvement should be incorporated into the overall assessment of AA severity rather than be assessed separately and that in a patient with LSS, overall AA severity is increased by concurrent unilateral or bilateral eyelash involvement. It was also agreed that eyelash hair involvement that results in functional or occupational impairment increases scalp AA severity.

The following were agreed on by the group regarding the severity of eyelash disease:

- Minimal gaps with even spacing along the eyelids on both eyes indicated limited disease (corresponding to Eyelash ClinRO Measure 1³⁷).
- Significant gaps or uneven spacing along the eyelids indicated moderate disease (corresponding to Eyelash ClinRO Measure 2³⁷).
- No notable eyelashes indicated severe disease (corresponding to Eyelash ClinRO Measure 3³⁷).

Beard Hair Involvement The group agreed that beard hair involvement should be incorporated into the overall assessment of AA severity rather than be assessed separately. The experts also reached consensus that in a patient with LSS, concurrent beard involvement increases overall AA severity, regardless of whether the beard has any cultural or religious significance.

Nail Involvement The experts concurred that nail involvement should be incorporated into the overall assessment of AA severity rather than be assessed separately. The participants also agreed that, in a patient with LSS, nail involvement increases overall AA severity. Fur-

Table 2. Expert Perspectives From Round 1 Regarding the Initiation of Systemic Treatment for Alopecia Areata Based on SALT Score

Participant SALT score threshold	No. of experts	Proportion of total (N = 64), %
What is the SALT score above which you would always consider initiating systemic therapy?		
≥10	1	1.6
≥20	7	10.9
≥25	3	4.7
≥30	5	7.8
≥40	6	9.4
≥50	27	42.2
≥60	1	1.6
≥70	2	3.1
NA ^a	12	18.8
What is the SALT score below which you would never consider initiating systemic therapy?		
≤5	4	6.3
≤10	15	23.4
≤15	1	1.6
≤20	15	23.4
≤25	9	14.1
≤30	1	1.6
≤35	1	1.6
≤90	1	1.6
NA ^a	17	26.6

Abbreviations: NA, not applicable; SALT, Severity of Alopecia Tool.

^a Additional factors identified as influencing the decision to commence systemic therapy included hair loss location, examination findings (eg, hair pull test results, trichoscopic findings), alopecia areata duration, quality of life outcomes, and treatment history and response.

thermore, consensus was achieved on considering nail involvement that resulted in functional or occupational impairment as sufficient criteria for initiating systemic therapy.

The following were agreed on by the group regarding the severity of nail disease:

- At least 1 nail with a little damage indicated mild nail disease (eg, pitted, rough, brittle, split) (corresponding to Nail ClinRO Measure 1³⁷).
- At least 1 moderately damaged nail indicated moderate nail disease (eg, pitted, rough, brittle, split) (corresponding to Nail ClinRO Measure 2³⁷).
- At least 1 very damaged nail (eg, pitted, rough, brittle, split) or the loss of at least 1 nail indicated severe nail disease (corresponding to Nail ClinRO Measure 3³⁷).

Quality of Life and Psychosocial Morbidity

Mood and Anxiety Disorder History | Participants agreed on the importance of psychosocial outcomes as a crucial criterion in assessing AA severity. The experts also concurred that in a patient with LSS, a history of anxiety, depression, or suicidal ideation attributed to or exacerbated by AA increases overall AA severity.

Quality of Life | Consensus was reached that, in a patient with LSS, increased overall AA severity may be increased by racial, ethnic, or religious factors, for example, if the beard has a special cultural or reli-

gious significance. Furthermore, experts agreed in the third video communication round that the DLQI³⁸ is not an adequate measure of quality of life in patients with AA, despite being commonly used to assess AA impact. However, in the absence of a validated, universal quality of life (QOL) measure, participants agreed that the overall severity rating of AA is not affected by a DLQI score of 0 to 5 and is increased by a DLQI score of 6 to 30.

Initiation of Systemic Treatment

Disease Surface Area (Scalp Involvement)

For the initiation of systemic treatment, careful consideration of disease surface area, specifically scalp involvement, is crucial. Table 2 summarizes expert perspectives from round 1 regarding the commencement of systemic therapies based on the SALT score.

Disease Duration

When considering AA episode duration, the experts agreed that patients with rapidly progressive AA may be eligible for systemic treatment, regardless of disease duration. In patients with AA that is not rapidly progressive, the minimum episode duration a patient must experience to be eligible for systemic treatment is 6 months; additionally, participants agreed that systemic treatment should not be precluded by a maximum duration, even though evidence suggests its lower likelihood of success in long-standing disease.^{15,39}

Number of AA Episodes and Relapse History

Consideration of the number of AA episodes and relapse history is an integral aspect of determining eligibility for systemic treatment. Consensus was reached among experts that such eligibility should not be contingent on the count of relapses, emphasizing a nuanced approach to treatment decisions.

Refractory Disease

In a patient with LSS, participants agreed that a history of inadequate response to topical and/or intralesional agents was sufficient criterion for commencing systemic therapy. Also, the experts agreed that, as a minimum, 2 topical and/or intralesional agents must be tried before commencing systemic therapy.

Trichoscopy and Examination Findings

In a patient with LSS, trichoscopic features associated with an adverse prognosis are not sufficient criteria for the initiation of systemic therapy. Experts also agreed that rapid AA onset, a positive diffuse hair pull test result, or an ophiasis distribution are sufficient criteria for the initiation of systemic therapy.

Cosmetic Camouflage

It was agreed that challenges in cosmetically concealing or camouflaging AA in patients with LSS were sufficient for initiation of systemic therapy. This acknowledgment underscores the importance of considering individual needs and experiences in treatment decisions.

Nonscalp Involvement

In a patient with LSS, concurrent unilateral eyebrow, beard, or nail involvement was considered insufficient criteria to commence systemic therapy. However, eyebrow, eyelash, or nail involvement result-

ing in functional or occupational impairment sufficed to commence systemic therapy.

Quality of Life and Psychosocial Morbidity

In a patient with LSS, a DLQI score between 0 and 10 is insufficient criteria to commence systemic therapy. However, a DLQI score of more than 10 or a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA was considered sufficient criteria.

Third-Party Funding of JAK Inhibitors

Overall, 26 questions explored factors associated with the funding of JAK inhibitors by third-party payers. A third-party payer was defined as the entity paying for the cost of treatment, such as an insurer or publicly funded health care system.

The group agreed that, regardless of SALT score, third-party payers should be encouraged to provide funding for JAK inhibitors to treat individuals with any of the following features:

- An AA episode lasting 12 months or more;
- Challenges with cosmetically concealing or camouflaging scalp areas affected by AA;
- Beard involvement when the beard has special cultural or religious significance;
- Nail involvement resulting in functional or occupational impairment;
- A history of anxiety, depression, or suicidal ideation due to or exacerbated by AA; and
- A DLQI score of more than 10.

Consensus was reached that the presence of a comorbidity responsive to a JAK inhibitor (eg, rheumatoid arthritis, atopic dermatitis) should alter the threshold for starting this treatment route, as well as the decision of which JAK inhibitor to prescribe. When a JAK inhibitor has achieved regulatory approval for a second disease in addition to AA (eg, AA and atopic dermatitis), the severity assessment of the other disease (eg, Eczema Area and Severity Index [EASI] score) was considered relevant to the decision to commence JAK inhibitor therapy for AA.

Additionally, experts were given the opportunity to record a free-text SALT score minimum for which third-party payers should be encouraged to provide funding for JAK inhibitor treatment for AA. Table 3 presents these responses and their frequencies among the experts.

Neither the number of AA relapses nor the duration of an episode were identified as prohibitive factors for third-party funding of JAK inhibitors. The group agreed that the following factors did not automatically warrant third-party funding of JAK inhibitor treatment:

- The number of AA relapses experienced by a patient;
- AA with isolated involvement of the eyebrows, eyelashes, beard, or nails;
- Trichoscopic features associated with adverse AA prognosis; and
- a DLQI score of 10 or less.

Outcomes Without Consensus

Consensus was not achieved for 46 questions in the first round, 25 questions in the second round, and 6 questions in the third round. Notably, no consensus was reached regarding whether eyelash involvement (unilateral or bilateral) or bilateral eyebrow involvement in a patient with LSS was sufficient for commencing systemic therapy. Consensus was not reached about encouraging third-party funding for JAK inhibitor

Table 3. Expert Perspectives From Round 1 Regarding Third-Party Funding of JAK Inhibitors Based on SALT Score

Participant SALT score threshold	No. of experts	Proportion of total (N = 64), %
Third-party payers should be encouraged to provide funding for JAK inhibitors to treat individuals who have a SALT score of:		
≥10	1	1.6
≥20	5	7.8
≥25	3	4.7
≥30	7	10.9
≥40	4	6.3
≥50	27	42.2
≥60	3	4.7
≥70	5	7.8
≥75	3	4.7
≥80	2	3.1
≥90	1	1.6
NA ^a	3	4.7

Abbreviations: JAK, Janus kinase; NA, not applicable; SALT, Severity of Alopecia Tool.

^a Additional factors identified as influencing the decision to commence systemic therapy included hair loss location, examination findings (eg, hair pull test results, trichoscopic findings), alopecia areata duration, quality of life outcomes, and treatment history and response.

therapy in patients with inadequate response to topical and/or systemic agents or rapidly progressive disease without first considering the SALT score.

Discussion

In an era of emerging treatments for AA, the need for a multidimensional severity assessment tool that accurately captures disease burden, streamlines clinical assessment, and guides management has been identified by leading international hair specialists.^{12,13} As a precursor, we undertook a large-scale global expert consensus study and, in doing so, identified several key determinants of AA severity and their relevance to the clinical decision to initiate systemic treatment.

Although experts agreed that the Alopecia Areata Investigator Global Assessment scale adequately defines scalp disease severity, they also concurred that nonscalp hair loss measures must be incorporated into an overall severity assessment tool. Furthermore, participants agreed that several factors were associated with an increase in AA severity independent of the percentage scalp hair loss. These factors included a history of 3 or more AA relapses, an episode lasting 12 months or more, rapid progression of disease indicated by a positive diffuse hair pull test result, involvement of facial hair (including involvement of eyebrow[s], eyelashes, or beard), the presence of nail disease, identification of trichoscopic features associated with adverse prognosis, and a history of inadequate response to 2 or more topical and/or 2 or more systemic agents. Several of these factors were also identified via expert consensus as sufficient criteria for the commencement of systemic therapy, even in the presence of LSS. Facial hair loss alone was considered insufficient to warrant systemic treatment initiation, unless concurrent scalp involvement, functional impairment, or adherence to cultural or religious requirements

were observed. Furthermore, in patients with AA that is not rapidly progressing, the experts agreed that a minimum episode duration of 6 months was required before starting systemic therapy, reflecting the spontaneous regrowth that may occur during this time.

The psychosocial impact of AA was underscored by near-unanimous agreement that a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA sufficed for systemic treatment initiation. Despite being used to measure QOL in AA by some clinicians, experts agreed that DLQI score was an inadequate measure in this context, presenting an argument for the development and validation of a more tailored QOL tool completed through future international collaborations. However, when DLQI is used to decide whether to initiate systemic treatment, a score of more than 10 was found to suffice for systemic treatment initiation, with experts acknowledging the possible discordance between objective AA severity and the personal burden of disease.

As newer treatments for AA emerge, dermatologists, funding agencies, and patient advocacy groups must work together to ensure appropriate and equitable allocation of health resources. JAK inhibitors signify a notable advancement in the treatment of AA; however, the considerable expense associated with this treatment may pose a barrier in resource-limited settings. This study sought to further characterize the perspectives of hair experts regarding guidelines for third-party payers for funding JAK inhibitors to treat AA. Including the perspectives of clinicians at this early stage is vital because of their practical experience with prescribing JAK inhibitors and pivotal role in ensuring effective, safe use. Although establishing eligibility criteria for treatment access is a separate task, experts concurred that third-party payers should be encouraged to fund JAK inhibitors for various reasons, irrespective of SALT score. Notably, no consensus was achieved on the number of prior therapies that should be attempted before encouraging funding for JAK inhibitor treatment. Given the transformative influence of JAK inhibitors on AA treatment, the areas lacking consensus emphasize the necessity of customizing prescription practices based on the systemic medication class, each exhibiting unique responses.

Limitations

Although considerable efforts were made in the design phase to produce a clear questionnaire, different interpretations of some

questions were noted through obtaining expert feedback. Of note, although two-thirds of the group reached consensus on many items, there remained significant dissent between experts on some issues. Further, an inherent flaw of the eDelphi design is that individual expert opinions may not necessarily be grounded in established evidence. This concern reflects the subjective nature of assessing and managing AA in a clinical setting, demonstrating the importance of reaching a consensus for establishing a globally adopted, cohesive tool. Additionally, expert representation across 6 continents decreased from the first round conducted via text-based eDelphi web application to the third round conducted via video conferencing, highlighting the challenges encountered when conducting global eDelphi surveys (eTable in Supplement 1). Not all experts were represented in the first 12 questions of the third round because of logistical difficulties arising from multiple time zones. Furthermore, the video conference was not chaired by an independent, nonvoting expert, thereby introducing potential bias. Finally, this study did not involve perspectives from patients or the public.

Conclusions

These findings are anticipated to provide a crucial foundation for the development of a multidimensional tool to adequately assess AA severity, ensuring a comprehensive understanding of the disease burden. This tool also will aim to aid in the identification of suitable candidates for both existing and emerging systemic therapies. Future research must assign weight to each of the domains that have been identified as contributing to AA severity. Patient and public involvement will be essential in this pursuit, capturing the voices of those who live with AA. Connected, harmonized patient registries will be useful moving forward for assessing treatment safety, efficacy, and quality of life outcomes.^{26,40}

The ASAMI study provides international expert consensus on factors that modulate AA disease severity and insight into current experts' thresholds for the initiation of systemic treatment. Identification of determinants of AA severity is the first step toward development of the ASAMI tool: a proposed international expert-defined clinical assessment tool for AA.

ARTICLE INFORMATION

Accepted for Publication: October 25, 2023.

Published Online: February 7, 2024.
doi:10.1001/jamadermatol.2023.5869

ASAMI Consensus Survey Study Group Authors:

Anthony Moussa, MBBS (Hons), MS, MSc, MMed; Michaela Bennett, MBBS, GradCertBioMedSc, BInfoTech; Dmitri Wall, MBChB, BAO, MSc Health Informatics; Nekma Meah, MBChB, MRCP(Derm); Katherine York, MBChB; Laita Bokhari, MPhil, Med; Leila Asfour, BSc, MBChB; Huw Rees, PhD; Leonardo Spagnoli Abraham, MD, MSc; Daniel Asz-Sigall, MD; Fitnat Buket Basmanav, PhD; Wilma Bergfeld, MD; Regina C. Betz, MD; Bevin Bhoyrul, MBBS, MRCP; Ulrike Blume-Peytavi, MD, PhD; Valerie Callender, MD; Vijaya Chitreddy, MBBS; Andrea Combalia, MD; George Cotsarelis, MD; Brittany Craiglow, MD; Rachita Dhurat, MD; Jeff Donovan, MD, PhD; Andrei Doroshkevich, MD; Samantha Eisman, MBChB; Paul Farrant, BSc,

MBBS; Juan Ferrando, MD; Aida Gadzhigorieva, MD, PhD, DMedSc; Jack Green, MBBS (Hons); Ramon Grimalt, MD, PhD; Matthew Harries, MBChB, PhD; Maria Hordinsky, MD; Alan Irvine, MD, DSc; Victoria Jolliffe, BChir, MA; Spartak Kaiumov, MD, PhD; Brett King, MD, PhD; Joyce Lee, MBBS, MRCP; Won-Soo Lee, MD, PhD; Jane Li, MBBS (Hons), BMedSci, PhD; Nino Lortkipanidze, MD, PhD; Amy McMichael, MD; Natasha Atanaskova Mesinkovska, MD, PhD; Andrew Messenger, MD; Paradi Mirmirani, MD; Elise Olsen, MD; Seth J. Orlow, MD, PhD; Yuliya Ovcharenko, MD, PhD; Bianca Maria Piraccini, MD, PhD; Rodrigo Pirmez, MD; Adriana Rakowska, MD, PhD; Pascal Reygagne, MD; Lidia Rudnicka, MD, PhD; David Saceda Corralo, MD, PhD; Maryanne Senna, MD; Jerry Shapiro, MD; Pooja Sharma, MBBS, MD; Tatiana Siliuk, MD; Michela Starace, MD, PhD; Poonkiat Suchonwanit, MD; Anita Takwale, MD; Antonella Tosti, MD; Sergio Vañó-Galván, MD, PhD; Willem I. Visser, MBChB, MFamMed, MMed, (Derm); Annika

Vogt, MD; Martin Wade, BMed Sci, MBBS; Leona Yip, MBChB, PhD, FADC; Cheng Zhou, MD; Rodney Sinclair, MBBS, MD.

Affiliations of ASAMI Consensus Survey Study

Group Authors: Sinclair Dermatology, East Melbourne, Victoria, Australia (Moussa, Bennett, Bokhari, Rees, Bhoyrul, Chitreddy, Eisman, Sharma, Sinclair); Hair Restoration Blackrock, Dublin, Ireland (Wall); National and International Skin Registry Solutions (NISR), Charles Institute of Dermatology, University College Dublin, Dublin, Ireland (Wall); St Helens & Knowsley National Health Service Trust, St Helens, United Kingdom (Meah); Manchester University, Faculty of Biology, Medicine and Health, Manchester, United Kingdom (Meah); Netcare Greenacres Hospital, Port Elizabeth, South Africa (York); Salford Royal Foundation Trust, Northern Care Alliance, Manchester, United Kingdom (Asfour); Trichology Unit of Hospital Regional da Asa Norte, Brasília-DF, Brazil (Abraham); Trichology

Clinic, Dermatology Department, Dr Manuel Gea Gonzalez General Hospital, Mexico City, Mexico (Asz-Sigall); Institute of Human Genetics, University Hospital of Bonn & University of Bonn, Bonn, Germany (Basmanav, Betz); Cleveland Clinic Foundation, Cleveland, Ohio (Bergfeld); Department of Dermatology, Venerology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany (Blume-Peytavi); Callender Dermatology and Cosmetic Center, Glenn Dale, Maryland (Callender); Dermatology Department, Hospital Clinic de Barcelona, Barcelona, Spain (Combalia, Ferrando); Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (Cotsarelis); Department of Dermatology, Yale School of Medicine, New Haven, Connecticut (Craiglow); LTMCM and LTMG Hospital Sion Mumbai, Mumbai, India (Dhurat); Donovan Hair Clinic, University of British Columbia, Whistler, British Columbia, Canada (Donovan); Center of Hair Treatment and Transplantation, St Petersburg, Russia (Doroshkevich); Australasian Hair and Wool Research Society, Melbourne, Victoria, Australia (Eisman, Sinclair); Brighton and Sussex University Hospitals National Health Service Trust, Brighton, United Kingdom (Farrant); Moscow Scientific & Practical Center of Dermatology, Venereology and Cosmetology, Russian Federation (Gadzhigoroeva); Department of Dermatology, Saint Vincent's Hospital, Victoria, Australia (Green, Li); Facultat de Medicina i Ciències de la Salut, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain (Grimalt); Salford Royal Hospital, Northern Care Alliance National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (Harries); Centre for Dermatology Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom (Harries); Department of Dermatology, University of Minnesota, Minneapolis (Hordinsky); Clinical Medicine, Trinity College Dublin, Dublin, Ireland (Irvine); Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom (Jolliffe); Clinic of Trichology and Cosmetology Nautilus, Saint-Petersburg, Russia (Kaiumov); Yale School of Medicine, New Haven, Connecticut (King); National Skin Centre, Singapore (J. Lee); Department of Dermatology, Yonsei University, Wonju College of Medicine, 20 Ilson-ro, Wonju, Gangwon-do, Republic of Korea (W. Lee); University of Melbourne, Melbourne, Victoria, Australia (Li); Department of Dermatology, Eastern Health, Melbourne, Victoria, Australia (Li); Skin Health Institute, Carlton, Melbourne, Victoria, Australia (Li); David Tvilidiani Medical University, Tbilisi, Georgia (Lortkipanidze); Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina (McMichael); Department of Dermatology, School of Medicine, University of California, Irvine (Mesinkovska); Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom (Messenger); The Permanente Medical Group, Vallejo, California (Mirmirani); Duke Dermatology Clinic, Durham, North Carolina (Olsen); Grossman School of Medicine, New York University, New York, New York (Orlow); Department of Infectious Diseases and Clinical Immunology, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine (Ovcharenko); Dermatology Unit, IRCCS Azienda

Ospedaliero-Universitaria di Bologna, Bologna, Italy (Piraccini, Starace); Department of Medical and Surgical Sciences University of Bologna, Bologna, Italy (Piraccini); Instituto de Dermatologia Professor Rubem David Azuly-Santa Casa de Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil (Pirmez); Department of Dermatology, Medical University of Warsaw, Warsaw, Poland (Rakowska, Rudnicka); Centre de Santé Sabouraud, Hôpital Saint Louis, Vellefaux, Paris, France (Reygagne); Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy (Corralo); Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts (Senna); Harvard Medical School, Harvard University, Boston, Massachusetts (Senna); Disorders of the Hair and Scalp, The Ronald O. Perleman Department of Dermatology, New York University School of Medicine, New York, New York (Shapiro); Hair Treatment and Transplantation Center, Saint Petersburg, Russian Federation (Siliuk); Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy (Starace); Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (Suchonwanit); Editorial Advisory Board, Indian Journal of Dermatology Venereology Leprosy (Takwale); Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida (Tosti); Dermatology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcalá, Madrid, Spain (Vaño-Galván); Trichology Unit, #TricoHRC Research Group, Madrid, Spain (Vaño-Galván); Division of Dermatology, Stellenbosch University, Cape Town, South Africa (Visser); Department of Dermatology, Venerology and Allergology, Clinical Research Center for Hair and Skin Science, Charité-Universitätsmedizin Berlin, Berlin, Germany (Vogt); The London Skin and Hair Clinic, London, United Kingdom (Wade); Skin Partners Specialist Dermatologists, Brisbane, Australia (Yip); Department of Dermatology, Peking University People's Hospital, Xicheng District, Beijing, China (Zhou); Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia (Sinclair).

Author Contributions: Drs Bennett and Moussa had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Moussa and Bennett contributed equally as co-first authors.

Concept and design: Moussa, Bennett, Wall, Meah, York, Bokhari, Asfour, Rees, Spagnol Abraham, Asz-Sigall, Bergfeld, Chitreddy, Dhurat, Doroshkevich, Eisman, Mirmirani, Sharma, Starace, Tosti, Sinclair.

Acquisition, analysis, or interpretation of data: Moussa, Bennett, Wall, York, Bokhari, Asfour, Basmanav, Betz, Bhoyrul, Blume-Peytavi, Callender, Combalia, Cotsarelis, Craiglow, Donovan, Doroshkevich, Farrant, Ferrando, Gadzhigoroeva, Green, Grimalt, Harries, Hordinsky, Irvine, Jolliffe, Kaiumov, King, J. Lee, W. Lee, Li, Lortkipanidze, McMichael, Mesinkovska, Messenger, Olsen, Orlow, Ovcharenko, Piraccini, Pirmez, Rakowska, REYGAGNE, Rudnicka, Saceda Corralo, Senna, Shapiro, Silyuk, Suchonwanit, Takwale, Vaño-Galván, Visser, Vogt, Wade, Yip, Zhou, Sinclair.

Drafting of the manuscript: Moussa, Bennett, Wall,

York, Bokhari, Asfour, Asz-Sigall, Chitreddy, Dhurat, Doroshkevich, Kaiumov, Saceda Corralo, Silyuk, Starace, Tosti, Yip.

Critical review of the manuscript for important intellectual content: Moussa, Bennett, Wall, Meah, York, Bokhari, Asfour, Rees, Spagnol Abraham, Asz-Sigall, Basmanav, Bergfeld, Betz, Bhoyrul, Blume-Peytavi, Callender, Combalia, Cotsarelis, Craiglow, Donovan, Eisman, Farrant, Ferrando, Gadzhigoroeva, Green, Grimalt, Harries, Hordinsky, Irvine, Jolliffe, King, J. Lee, W. Lee, Li, Lortkipanidze, McMichael, Mesinkovska, Messenger, Mirmirani, Olsen, Orlow, Ovcharenko, Piraccini, Pirmez, Rakowska, REYGAGNE, Rudnicka, Saceda Corralo, Senna, Shapiro, Sharma, Suchonwanit, Takwale, Vaño-Galván, Visser, Vogt, Wade, Zhou, Sinclair.

Statistical analysis: Moussa, Wall, Bokhari, Bhoyrul, Sharma, Wade.

Obtained funding: Ferrando, Kaiumov, Sinclair.

Administrative, technical, or material support:

Moussa, Bennett, Wall, York, Bokhari, Rees, Green, Hordinsky, Jolliffe, J. Lee, Mesinkovska, Mirmirani, Zhou, Sinclair.

Supervision: Wall, Meah, Bokhari, Asfour, Asz-Sigall, Chitreddy, Combalia, Dhurat, Eisman, Ferrando, Grimalt, Irvine, W. Lee, Li, Mesinkovska, Piraccini, Saceda Corralo, Shapiro, Starace, Tosti, Vaño-Galván, Visser, Sinclair.

Conflict of Interest Disclosures: Dr Wall reported personal fees from Lilly, Pfizer, Almirall, National and International Skin Registry Solutions, grants from Pfizer, outside the submitted work, and employment by National and International Skin Registry Solutions. Dr Wall is a principal investigator of Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS) Ireland and a steering committee member of GRASS Ireland, GRASS UK, and GRASS International. Dr Meah reported membership in and being secretary for the British Hair and Nail Society and participation in the Secure Alopecia Steering Committee for Grass UK. Dr Asfour reported personal fees from AbbVie and Medthority outside the submitted work. Dr Betz reported personal fees from Pfizer outside the submitted work, grants from the German Research Foundation (DFG). Dr Blume-Peytavi reported involvement with the Concert Pharm Clinical study, personal fees from Pfizer, Eli Lilly, Sanofi Regeneron, Galderma, Laboratoires Bailleuil, and AbbVie outside the submitted work. Dr Callender reported grants from Admiral, Aerolase, AbbVie, Arcutis, Avava, Beiersdorf, Cutera, Dermavant, Eli Lilly, Galderma, Juene Aesthetic, L'Oreal, OrthoDerm, Pfizer, Prolineum, Janssen, Scientis, Sente, SkinCeuticals, Symatose, Teoxane, UpToDate, and Acne Store outside the submitted work. Dr Craiglow reported personal fees from AbbVie, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, and Eli Lilly outside the submitted work. Dr Donovan reported personal fees from Pfizer during the conduct of the study and from Vichy outside the submitted work. Dr Eisman reported serving on the Australian Dermatology Advisory Alopecia Areata Board and Lebrizikumab Advisory Board for Eli Lilly, being a committee member of Australasian Hair and Wool Research Society, and involvement with clinical trials associated with AbbVie, Arena Pharmaceutical, Boston Pharmaceuticals, Botanix, Bristol Myers Squibb, Dermaliq Therapeutics, Dermira, Eli Lilly and Company, Evelo Biosciences, Immunicon Therapeutics, Janssen, Kobiolabs, Kymab, LEO

Pharma, Novartis, Pfizer, Regeneron, Sanofi, Suzhou Connect Biopharmaceuticals, TEVA Pharmaceuticals, Tigermed, and Zai Lab. Dr Harries reported grants from National Institute for Health and Care Research Manchester Biomedical Research Centre during the conduct of the study, involvement with Soterios clinical trial (Manentia), and financial support to institution from Eli Lilly and Pfizer outside the submitted work; and involvement with updating British Association of Dermatologist alopecia areata guidelines. Dr Hordinsky reported involvement in published research on a validated tool for assessing the extent of alopecia areata disease Dr Irvine reported grants from Pfizer during the conduct of the study. Dr King reported personal fees from Pfizer, Eli Lilly, and Concert. Dr McMichael reported personal fees from Pfizer, UCB, Sun Pharmaceuticals, Lilly, Janssen, Arcutis, Leo, Revian, and grants from Incyte outside the submitted work. Dr Mesinkovska reported personal fees from Lilly, Concert, Pfizer, grants from Lilly, Pfizer, Concert, and AbbVie outside the submitted work, as well as involvement with the National Alopecia Areata Foundation and American Hair Research Society. Dr Messenger reported personal fees from Pfizer, Manentia, and UpToDate outside the submitted work. Dr Mirmirani reported grants from Eli Lilly, Pfizer, and Sun Pharmaceuticals paid to institution outside the submitted work. Dr Olsen reported personal fees from Lilly and Pfizer outside the submitted work. Dr Orlow reported involvement with Almirall Srl and R2 Technologies. Dr Pirmez reported personal fees from Pfizer and Eli Lilly outside the submitted work. Dr Reygagne reported personal fees from Novartis, Lilly, involvement with BMS research during the conduct of the study, and personal fees from Pierre Fabre and L'Oréal outside the submitted work. Dr Senna reported personal fees from Pfizer, Lilly, Inmagene, and AbbVie during the conduct of the study, as well as Kintor and L'Oréal outside the submitted work. Dr Shapiro reported personal fees from Lilly and Pfizer during the conduct of the study and outside the submitted work. Dr Takwale reported personal fees from Pfizer and Sanofi outside the submitted work. Dr Tosti reported personal fees from Eli Lilly, Pfizer, DS Laboratories, BMS, Almirall, Tirthy Madison, and Myovant outside the submitted work. Dr Vaño-Galván reported personal fees from Lilly and Pfizer during the conduct of the study. Dr Vogt reported personal fees from Bayer, Sanofi, Trichology Experts Network, and Galderma outside the submitted work, as well as membership in DDG Work Group Pediatric Dermatology, European Hair Research Society, Deutsche Dermatologische Gesellschaft, Berliner Dermatologische Gesellschaft, and Arbeitsgemeinschaft Dermatologische Forschung. Dr Sinclair reported personal fees from Pfizer, Eli Lilly, AbbVie, Reistone, Sun Pharma, Bristol Myers Squibb, founding and directing Samson Clinical outside the submitted work; in addition, Dr Sinclair had the following patents issued: AU2017210523, EP19205898.0, HK 42020012896.5, JP2020-067194, SG10202002705Y, US16252107 1116770; a patent pending for US16344288/US20190269684; and was a committee member of Australasian Hair and Wool Research Society. No other disclosures were reported.

Data Sharing Statement: See Supplement 2.

Additional Contributions: Lachlan Coulthard, BlinTech, provided administrative and information

technology support, for which no compensation was received.

REFERENCES

1. Gilhar A, Etzioni A, Paus R. Alopecia areata. *N Engl J Med*. 2012;366(16):1515-1525. doi:10.1056/NEJMr1103442
2. Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. *J Invest Dermatol*. 2014;134(4):1141-1142. doi:10.1038/jid.2013.464
3. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ III. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. *Mayo Clin Proc*. 1995;70(7):628-633. doi:10.4065/70.7.628
4. Harries M, Macbeth AE, Holmes S, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. *Br J Dermatol*. 2022;186(2):257-265. doi:10.1111/bjd.20628
5. Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. *J Am Acad Dermatol*. 2021;84(6):1594-1601. doi:10.1016/j.jaad.2020.09.028
6. Wall D, Rees H, Bokhari L, Meah N, York K, Sinclair R. Signposts to the promised land in alopecia areata. *J Invest Dermatol*. 2023;143(1):9-10. doi:10.1016/j.jid.2022.08.031
7. Vélez-Muñoz RDC, Peralta-Pedrero ML, Jurado-Santa Cruz F, Morales-Sánchez MA. Psychological profile and quality of life of patients with alopecia areata. *Skin Appendage Disord*. 2019;5(5):293-298. Published online March 20, 2019. doi:10.1159/000497166
8. Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. *J Invest Dermatol Symp Proc*. 2020;20(1):S62-S68. doi:10.1016/j.jisp.2020.05.007
9. Macbeth AE, Holmes S, Harries M, et al. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. *Br J Dermatol*. 2022;187(1):73-81. doi:10.1111/bjd.21055
10. Olsen EA, Hordinsky MK, Price VH, et al; National Alopecia Areata Foundation. Alopecia areata investigational assessment guidelines—part II. *J Am Acad Dermatol*. 2004;51(3):440-447. doi:10.1016/j.jaad.2003.09.032
11. Olsen EA, Canfield D. SALT II: a new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. *J Am Acad Dermatol*. 2016;75(6):1268-1270. doi:10.1016/j.jaad.2016.08.042
12. King BA, Senna MM, Ohya M, et al. Defining Severity in alopecia areata: current perspectives and a multidimensional framework. *Dermatol Ther (Heidelb)*. 2022;12(4):825-834. Published online March 31, 2022. doi:10.1007/s13555-022-00711-3
13. King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. *J Am Acad Dermatol*. 2022;86(2):359-364. doi:10.1016/j.jaad.2021.08.043
14. Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed

by JAK inhibition. *Nat Med*. 2014;20(9):1043-1049. doi:10.1038/nm.3645

15. Moussa A, Bokhari L, Sinclair R. Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape. *Wounds Pract Res*. 2022;30(1):24-33. doi:10.33235/wpr.30.1.24-33
16. US Food and Drug Administration. FDA approves first systemic treatment for alopecia areata. Accessed January 4, 2024. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata>
17. European Medicines Agency. Olumiant. Accessed January 4, 2024. <https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant>
18. Medicines & Healthcare Products Regulatory Agency. Olumiant key facts. Accessed January 4, 2024. <https://cms.mhra.gov.uk/pip/mhra-100265-pip01-21>
19. Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. *J Am Acad Dermatol*. 2020;83(1):123-130. doi:10.1016/j.jaad.2020.03.004
20. Sinclair R. Alopecia areata: progress, but who pays. *Br J Dermatol*. 2022;186(2):206-207. doi:10.1111/bjd.20712
21. Gerbens LA, Boyce AE, Wall D, et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. *Trials*. 2017;18(1):87. doi:10.1186/s13063-016-1765-7
22. Gerbens LAA, Apfelbacher CJ, Irvine AD, et al; international TREAT Registry Taskforce. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo and systemic therapy registries. *Br J Dermatol*. 2019;180(4):790-801. doi:10.1111/bjd.16714
23. Spuls PI, Gerbens LAA, Apfelbacher CJ, et al. The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: an initiative to harmonize data collection across national atopic eczema photo and systemic therapy registries. *J Invest Dermatol*. 2017;137(9):2014-2016. doi:10.1016/j.jid.2017.05.014
24. Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. *PLoS Med*. 2011;8(1):e1000393. doi:10.1371/journal.pmed.1000393
25. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QQuality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. *BMJ Qual Saf*. 2016;25(12):986-992. doi:10.1136/bmjqs-2015-004411
26. Wall D, Meah N, York K, et al. A global eDelphi exercise to identify core domains and domain items for the development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS). *JAMA Dermatol*. 2021;157(4):1-11. doi:10.1001/jamadermatol.2020.5839
27. Gupta UG, Clarke RE. Theory and applications of the Delphi technique: a bibliography (1975-1994). *Technol Forecast Soc Change*. 1996;53(2):185-211. doi:10.1016/S0040-1625(96)00094-7

28. de Villiers MR, de Villiers PJ, Kent AP. The Delphi technique in health sciences education research. *Med Teach*. 2005;27(7):639-643. doi:10.1080/13611260500069947
29. Toronto C. Considerations when conducting e-Delphi research: a case study. *Nurse Res*. 2017;25(1):10-15. doi:10.7748/nr.2017.e1498
30. Welpi. Accessed January 23, 2022. <https://www.welpi.com/en/About.html>
31. Zoom Video Communications. Zoom software. Accessed April 30, 2022. <https://zoom.us/>
32. Poll Everywhere. Poll Everywhere software. Accessed April 30, 2022. <https://www.poll Everywhere.com/>
33. Likert R. A technique for the measurement of attitudes. *Arch Psychol*. 1932;22(140):55.
34. Sullivan GM, Artino AR Jr. Analyzing and interpreting data from Likert-type scales. *J Grad Med Educ*. 2013;5(4):541-542. doi:10.4300/JGME-5-4-18
35. IBM SPSS Statistics for Windows 28. Accessed January 4, 2024. <https://www.ibm.com/support/pages/downloading-ibm-spss-statistics-28>
36. Wyrwich KW, Kitchen H, Knight S, et al. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. *Br J Dermatol*. 2020;183(4):702-709. doi:10.1111/bjd.18883
37. Wyrwich KW, Kitchen H, Knight S, et al. Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. *Am J Clin Dermatol*. 2020;21(5):725-732. doi:10.1007/s40257-020-00545-9
38. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. *Clin Exp Dermatol*. 1994;19(3):210-216. doi:10.1111/j.1365-2230.1994.tb01167.x
39. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. *J Am Acad Dermatol*. 2006;55(3):438-441. doi:10.1016/j.jaad.2006.05.008
40. Wall D, Alhusayen R, Arents B, et al. Learning from disease registries during a pandemic: moving toward an international federation of patient registries. *Clin Dermatol*. 2021;39(3):467-478. doi:10.1016/j.clindermatol.2021.01.018